Amgen Hits Primary Endpoint In Sjögren's Trial, But Approval Filing Awaits Another Trial Data

Amgen reported encouraging topline results from its Phase 3 OASIZ 301 trial of dazodalibep in adults with Sjögren's disease and moderate-to-severe systemic disease activity. Positive late-stage efficacy data could support the drug's regulatory pathway and expand Amgen's autoimmune-disease pipeline, although the article provides no detailed efficacy or safety metrics.